Roche has ramped up its investment in NVIDIA's AI chips, launching an upscaled hybrid-cloud AI factory that it believes is ...

Sales of Voxzogo for achondroplasia grew more than a quarter in 2025 to reach $927 million, making it BioMarin's biggest seller, but the company has predicted that growth will slow in 2026, with a ...

A federal judge has pushed back against attempts by HHS Secretary Robert F Kennedy Jr to overhaul immunisation policy in the US, blocking changes to the recommended schedule as well as his ...

Rentschler taps biopharma vet to lead ops. Rentschler Biopharma, the German CDMO with offices in Massachusetts and Stevenage, ...

AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...

In order to discuss this topic further, pharmaphorum spoke with Sheila Diamond, director of scientific engagement at Medidata ...

Pharmaceutical organisations rarely struggle to write strategy. They struggle to protect it. Global brand teams define ambition precisely. Segmentation models are refined. Launch plans are ...

The analysis – reported at the European Association of Urology (EAU) annual congress in London, UK – shows that it is "no longer rational to reject prostate cancer screening on one hand while ...

The US regulator has cleared its Arexvy RSV shot for adults in that age group who are at increased ​risk of lower respiratory ...

Johnson & Johnson has revealed early clinical data with a new formulation of its FGFR inhibitor erdafitinib that suggests it could become the first targeted treatment for early‑stage bladder cancer.

Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD). Extending the label for Kerendia is a strategic priority for ...

Around half a million women in England will soon be able to access a non-hormonal treatment for hot flushes associated with ...